Cytosorbents Corp - Common Stock (CTSO) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CTSO on Nasdaq
Shares outstanding
63,013,241
Price per share
$0.68
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,720,742
Total reported value
$10,688,307
% of total 13F portfolios
0%
Share change
+504,560
Value change
+$306,470
Number of holders
47
Price from insider filings
$0.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cytosorbents Corp - Common Stock (CTSO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AVENIR CORP 8.3% +43% $3,817,972 +$1,559,392 5,230,099 +69% AVENIR CORP 31 Dec 2025
SATTERFIELD THOMAS A JR 6.6% $4,638,686 3,998,867 Thomas A. Satterfield, Jr. 13 Jan 2025
Avenue Venture Opportunities Fund, L.P. 5.7% $4,356,117 3,755,273 Avenue Capital Management II, L.P. 26 Jun 2024
Skylands Capital, LLC 4.8% -6% $3,483,134 +$256,453 3,002,702 +7.9% Skylands Capital, LLC 31 Mar 2025
VANGUARD GROUP INC 3.1% -57% $2,261,479 -$2,261,479 1,949,551 -50% The Vanguard Group 31 Mar 2025

As of 31 Dec 2025, 47 institutional investors reported holding 16,720,742 shares of Cytosorbents Corp - Common Stock (CTSO). This represents 27% of the company’s total 63,013,241 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cytosorbents Corp - Common Stock (CTSO) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
AVENIR CORP 8.3% 5,230,099 +2.9% 0.36% $3,343,079
VANGUARD GROUP INC 3.5% 2,204,294 0% 0% $1,408,544
Skylands Capital, LLC 2.9% 1,854,515 -13% 0.16% $1,185,406
NEUBERGER BERMAN GROUP LLC 2.6% 1,625,640 +1.7% 0% $1,039,597
CM Management, LLC 2.3% 1,476,500 +15% 0.8% $943,779
BlackRock, Inc. 1.2% 770,551 +0.75% 0% $492,536
Sargent Investment Group, LLC 0.97% 612,000 -17% 0.05% $391,190
GEODE CAPITAL MANAGEMENT, LLC 0.96% 603,767 +0.39% 0% $386,034
Pathstone Holdings, LLC 0.79% 499,955 0% $319,571
CIBC Private Wealth Group LLC 0.27% 172,649 0% 0% $110,357
STATE STREET CORP 0.25% 159,293 0% 0% $101,820
CITADEL ADVISORS LLC 0.24% 149,279 +127% 0% $95,419
GSA CAPITAL PARTNERS LLP 0.24% 148,374 +32% 0.01% $95,000
OSAIC HOLDINGS, INC. 0.21% 130,419 0% 0% $83,447
MORGAN STANLEY 0.18% 116,479 +8.6% 0% $74,454
UBS Group AG 0.18% 115,272 +0.06% 0% $73,659
RAYMOND JAMES FINANCIAL INC 0.17% 108,702 -0.02% 0% $69,482
RENAISSANCE TECHNOLOGIES LLC 0.16% 100,120 -26% 0% $63,997
NORTHERN TRUST CORP 0.15% 92,540 +1.1% 0% $59,151
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.13% 83,363 -15% 0% $53,286
Key Client Fiduciary Advisors, LLC 0.12% 78,457 0% 0.02% $50,150
Waverly Advisors, LLC 0.09% 55,556 0% 0% $35,511
STIFEL FINANCIAL CORP 0.08% 48,000 0% 0% $30,682
BANK OF AMERICA CORP /DE/ 0.06% 38,706 +0.01% 0% $24,732
GOLDMAN SACHS GROUP INC 0.06% 35,952 -41% 0% $22,980

Institutional Holders of Cytosorbents Corp - Common Stock (CTSO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,720,742 $10,688,307 +$306,470 $0.64 47
2025 Q3 16,334,989 $15,255,905 -$76,176 $0.93 48
2025 Q2 16,439,150 $20,747,017 -$475,512 $1.28 43
2025 Q1 16,936,549 $16,946,108 +$1,621,898 $1.00 47
2024 Q4 15,331,894 $14,135,595 -$1,258,331 $0.91 49
2024 Q3 16,479,547 $24,719,503 -$163,841 $1.50 52
2024 Q2 16,466,687 $11,576,845 -$649,269 $0.70 44
2024 Q1 17,587,924 $16,695,355 -$483,723 $0.95 48
2023 Q4 18,066,999 $20,043,725 +$3,216,187 $1.11 52
2023 Q3 15,225,693 $28,618,581 -$152,760 $1.88 52
2023 Q2 15,228,799 $54,658,487 +$137,905 $3.59 58
2023 Q1 15,164,229 $51,235,010 +$1,680,617 $3.37 57
2022 Q4 14,633,483 $22,639,263 -$45,975 $1.55 47
2022 Q3 13,738,883 $18,678,835 -$1,556,761 $1.36 51
2022 Q2 15,471,130 $33,885,658 -$6,118,886 $2.19 68
2022 Q1 18,023,750 $57,468,184 +$256,084 $3.19 81
2021 Q4 17,787,059 $74,549,808 -$8,090,953 $4.19 89
2021 Q3 18,365,550 $149,202,914 +$6,984,615 $8.12 93
2021 Q2 17,524,476 $132,378,236 -$233,053 $7.55 97
2021 Q1 17,470,204 $151,609,944 -$1,998,575 $8.68 91
2020 Q4 17,574,310 $140,069,028 +$3,065,684 $7.97 89
2020 Q3 17,195,121 $137,138,701 +$46,357,178 $7.98 94
2020 Q2 11,233,329 $111,252,626 +$14,117,068 $9.90 89
2020 Q1 9,938,360 $76,782,098 +$8,994,470 $7.73 79
2019 Q4 8,941,247 $34,418,814 +$1,513,313 $3.85 70
2019 Q3 8,444,748 $42,473,266 -$1,062,816 $5.03 66
2019 Q2 8,514,726 $56,282,437 +$525,949 $6.61 68
2019 Q1 8,508,451 $64,405,572 -$1,162,319 $7.57 71
2018 Q4 8,656,316 $69,927,146 +$1,133,626 $8.08 82
2018 Q3 8,196,875 $105,728,460 +$5,077,024 $12.90 78
2018 Q2 7,799,450 $88,919,578 +$45,837,712 $11.40 72
2018 Q1 3,924,758 $27,669,000 +$5,315,910 $7.05 47
2017 Q4 3,206,188 $20,847,000 +$4,718,786 $6.50 43
2017 Q3 2,481,878 $15,385,000 +$3,763,184 $6.20 30
2017 Q2 1,938,263 $8,335,000 -$2,210,646 $4.30 30
2017 Q1 2,432,898 $10,945,000 +$4,437,832 $4.50 33
2016 Q4 1,594,528 $8,689,000 +$49,086 $5.45 37
2016 Q3 1,568,958 $10,038,360 -$1,210,437 $6.40 34
2016 Q2 1,773,199 $8,063,000 +$413,105 $4.55 33
2016 Q1 1,405,899 $5,507,447 +$5,695 $3.92 31
2015 Q4 1,375,701 $7,660,000 -$173,999 $5.57 38
2015 Q3 1,350,065 $8,514,000 +$690,433 $6.30 30
2015 Q2 1,241,972 $7,625,037 +$743,226 $6.14 29
2015 Q1 908,197 $11,940,236 +$7,890,541 $13.19 27
2014 Q4 394,240 $3,921,376 +$1,051,376 $9.96 9